Human TL1A / TNFSF15 Protein, Fc Tag, active trimer, low endotoxin (MALS verified)

사용자 리뷰
제품 번호/규격
가격
수량
TLA-H5263-100ug
$380.00
TLA-H5263-1mg (500ug X 2)
$2380.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Synonyms

    TL1A, VEGI, TNFSF15

  • Source

    Human TL1A Protein, Fc Tag (TLA-H5263) is expressed from human 293 cells (HEK293). It contains AA Val 84 - Leu 251 (Accession # O95150-1).

    Predicted N-terminus: Pro

  • Molecular Characterization

    This protein carries a human IgG1 Fc tag at the N-terminus.

    The protein has a calculated MW of 85.1 kDa. The protein migrates as 95-110 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

  • SDS-PAGE

    TL1A SDS-PAGE

    Human TL1A Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    TL1A SEC-MALS

    The purity of Human TL1A Protein, Fc Tag (Cat. No. TLA-H5263) is more than 95% and the molecular weight of this protein is around 175-210 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     TL1A ELISA

    Immobilized Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) at 5 μg/mL (100 μL/well) can bind Human TL1A Protein, Fc Tag (Cat. No. TLA-H5263) with a linear range of 0.5-16 ng/mL (QC tested).

    Protocol
  •  TL1A ELISA

    Immobilized Human TL1A Protein, Fc Tag (Cat. No. TLA-H5263) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-TL1A Antibody, Human IgG1 with a linear range of 0.2-8 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     TL1A SPR

    Human TL1A Protein, Fc Tag (Cat. No. TLA-H5263) immobilized on CM5 Chip can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with an affinity constant of 0.621 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  TL1A SPR

    Human TL1A Protein, Fc Tag (Cat. No. TLA-H5263) immobilized on CM5 Chip can bind Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) with an affinity constant of 1.05 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

사용자 리뷰
댓글 남기기

배경 소개

TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Tumor necrosis factor superfamily member 15

  • 카테고리:

  • 상장 의약품 수:

    0 상세

  • 임상 의약품 수:

    18 상세

  • 최고 개발 단계:

    Phase 3 Clinical

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
  • 배경
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호